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SchizophreniaThe computer-based CogState Research Battery (CSRB) proposes a test structure which follows MATRICS recom-
mended cognitive domains but lacks direct comparison to pen and paper batteries in ﬁrst-episode psychosis
(FEP). The aim of this study was to compare performances obtained with the CSRB and a pen and paper battery
in a historical cohort of FEP patients. Among patients entering an early intervention program between 2003 and
2014, separate cohorts completed the traditional pen and paper cognitive battery (n = 182) and the CSRB (n =
97). Composite z-scores were derived using normative data of matched controls (n = 64 pen and paper, n = 69
CSRB) and were compared between the two batteries for the 7 cognitive domains. The cohort tested using the
CSRB performed better on the domains of processing speed, attention, visual memory, and verbal memory than
the cohort tested using the pen and paper battery (all p b 0.001). Performance did not differ between the two
types of batteries for the working memory, executive functions, and social cognition domains. Cognitive proﬁles
identiﬁed in the two patient cohortswere similar, with verbalmemory being themost impaired domain. Better per-
formances on the CSRB may be primarily due to the minimal demand of the computerized tests on graphomotor
abilities and reading speed compared to the pen and paper tests. Our investigation offers a better understanding
on how the results obtained with computerized batteries may compare to earlier work done with traditional tests.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent years, computerized cognitive batteries havebeen increasingly
used in schizophrenia research, particularly in randomized-control
trials which require retesting participants. This testing modality is
attractive to researchers for many reasons, namely precise stimulus
presentation and response recording, automated administration and
scoring, reduced administration and scoring time, and the possibility
of multiple equivalent alternate (Collie et al., 2001, 2003). It is impor-
tant to better understand how the results from such batteries compare
to previous reports using traditional pen and paper neuropsychological
tests. So far, research focusing on computerized neurocognitive
batteries involved mostly patients with chronic schizophrenia and
investigated their construct validity (Forbes et al., 2012; Irani et al.,
2012; Pietrzak et al., 2009a, 2009b; Ritsner et al., 2006; Silverstein
et al., 2010; Snyder et al., 2008; Yoshida et al., 2011).University Institute, Frank B
, Quebec, H4H 1R3, Canada.
enoit).
Inc. This is an open access article unThe use of computerized cognitive batteries in the early phases of
schizophrenia or related psychotic disorders has not yet been sufﬁciently
validated. The CogState Research Battery’s (CSRB) structure follows the
recommended MATRICS cognitive domains of processing speed, atten-
tion, working memory, visual learning and memory, verbal learning
and memory, executive functions, and social cognition for research in
schizophrenia (Nuechterlein et al., 2004).This battery has been
previously validated in a chronic schizophrenia sample against the pen
and paper MATRICS Consensus Cognitive Battery (MCCB) in chronic
schizophrenia (Pietrzak et al., 2009a). Strong correlations were found
between the performance on each test of the CSRB and the MCCB in
control and patient samples and sensitivity to deﬁcits was comparable
(Pietrzak et al., 2009a). To date, the CSRB has not been directly compared
to a pen and paper battery in a sample of patients experiencing psychosis
in ﬁrst-episode psychosis (FEP). It is unclear whether resulting cognitive
performance would be equivalent in this population since factors like
age, familiarity with computers, and inclusion of all subtypes of psychosis
in a sample of mostly out-patients as opposed to samples limited to
schizophrenia or low-functioning patients may inﬂuence the outcome.
This studyaims to compare the cognitiveperformanceof FEPpatients as
measured by two different batteries covering the 7 MATRICS-suggested
cognitive domains; one in conventional pen and paper form and theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Early Intervention Program for Psychoses (PEPP-Montreal) are
approached for cognitive testing. In 2010, the program switched from
their pen and paper battery to the CSRB, giving us the unique opportunity
to compare the results of these batteries in a historical cohort design.
Since we are studying a FEP cohort, we expect their level of cognitive im-
pairment to be milder than what was reported in the investigation of
Pietrzak et al. (2009a) of patients who have been ill for an average of
20 years. We also expect that cognitive proﬁles will be similar between
the two batteries but that performancemay differwhen separate cogni-
tive domains are compared according to testing modalities.2. Methods
2.1. Participants
All patients were recruited and treated through the PEPP-Montreal,
a specialized early intervention service at the Douglas Mental Health
University Institute in Montreal, Canada. People aged 14 to 35 years
from the local catchment area suffering from affective and non-
affective psychosis were admitted to the program, the majority as out-
patients. Patients enrolled had not taken antipsychotic medication for
more than one month, and had an IQ higher than 70. Diagnoses were
established according to the Structured Clinical Interview for DSM-IV
(First et al., 1998) and conﬁrmed between two senior research psychia-
trists co-authors of this study (A.M. & R.J.). For complete programdetails
see Malla et al. (2003) or http://www.douglas.qc.ca/clinical-services/
adults/specialized/pepp/contact.asp?l=e). All patients entering the
program were presented information regarding a longitudinal study
of cognition outcome in FEP and data from patients who signed the
consent form were used in this study.
Healthy control participantswere also recruited from the community
for the same longitudinal study and were matched for age, gender, and
parental socioeconomic status (SES) to the patients. Inclusion criteria
for healthy controls included no history of Axis I disorders, neurological
diseases, or traumatic brain injury, and no ﬁrst-degree family member
suffering from schizophrenia or related psychosis.
Research protocols were approved by the Douglas Mental Health
University Institute research ethics board and McGill University Faculty
of Medicine review board.
At the time of this analysis, 521 patients met the inclusion criteria for
this study. Of those, 87 refused to sign the consent form, 104 could not be
scheduled for testing and 51 had incomplete neuropsychological data,
and therefore had to be excluded. Final analyses include 182 patients
and 64 healthy controls who completed the pen and paper battery and
97 patients and 69 controls who completed the CSRB.Table 1
Demographic and clinical variables.
Patients Paper group
(n = 182)
Patients
(n = 97
Age 23.71 (3.63) 24.09 (5.
Gender (M:F) 129:53 76:21
Parental SESa,b 2.86 (1.10) 2.71 (1.0
Years of educationc 11.74 (2.34) 11.85 (2.
Antipsychotics total dose (mg/day in clz equivalents)a 484.40 (859.34) 312.56 (2
Symptom levelsa
SAPS total 15.18 (15.96) 11.40 (12
SANS total 24.41 (13.44) 20.19 (12
a Due to incomplete records sample sizes are as follows for Parental SES: Patients Paper grou
group n = 67; for Years of education: Patient Paper n = 177, Patients CSRB n = 85, Controls
n = 159, Patients CSRB group n = 97;for SAPS total: Patients Paper group n = 171, Patients C
n = 88.
b Hollingshead parental socio-economic status, in which 1 = highest and 4 = lowest.
c Post-hoc analyses show: Patient Paper, Patient CSRB b Controls Paper, Controls CSRB.Patients with complete neuropsychological data did not differ from
those with missing data on sex (Χ2 = 1.472, p = 0.225) or age (t =
1.403, p=0.152). However, patients who did not complete the evalua-
tion had signiﬁcantly lower symptom levels on the Scale for Assessment
of Positive Symptoms (SAPS; (Andreasen, 1984b) (t = 2.430, p =
0.015) and the Scale for the Assessment of Negative Symptoms (SANS;
(Andreasen, 1984a) (t= 2.153, p= 0.032). Patients with more severe
symptoms may have been utilizing clinical services more frequently
and consequently may have been easier to schedule for testing com-
pared to patients with minimal symptoms which visited the clinic less
frequently. The demographic information for the groups included in
the main analyses can be found in Table 1.
2.2. Measurements
All patients were approachedwithin the ﬁrst 6 months of treatment
for the cognitive assessment, which had been in pen and paper format
between 2003 and 2010. Since September 2010, a new testing protocol
was put in place, which includes the CSRB and therefore, the type of
cognitive assessment could not be randomized. Testing with healthy
controls was done during the same time periods with each battery.
Cognitive assessments of patients were done on average 13.74 weeks
(median: 8.29) after intake into treatment for those who did the pen
and paper battery and 16.18 weeks (median: 9.86) after intake for
those who did the CSRB, however the difference was not statistically
signiﬁcant (t=−0.920, p= 0.358). Assessments took place when pa-
tientswere in a stable enough but not necessarily an asymptomatic con-
dition, and were administered by trained research staff or graduate
students under the supervision of an accredited neuropsychologist
(M.L.). Cognitive assessments were done on site at PEPP-Montreal and
evaluators were supervised by a neuropsychologist (M.L.) for both pen
and paper and CSRB protocols. Regarding the CSRB administration, the
evaluator remained in the room while the patients underwent testing
to explain the tasks, verify that theywere performedoptimally and record
any relevant observations. This also ensured that data were recorded
properly; therefore only two patients had incomplete data among those
eligible for the CSRB, due to a computer problem (excluded due to
incomplete data: pen & paper: 15%, CSRB: 1%; χ2 = 22.31, p b 0.001).
2.3. Demographic and clinical data
The following informationwas collected at the time of neurocognitive
testing to characterize the two patient groups: age, type and dosage
of antipsychotics taken daily, and parental SES measured with the
Hollingshead two-factor index (Hollingshead, 1965). Symptom assess-
ments with the SAPS and SANS are done at multiple predeterminedCSRB group
)
Controls Paper group
(n = 64)
Controls CSRB group
(n = 69)
Statistic p
10) 24.09 (2.91) 24.77 (6.39) F = 0.929 0.427
43:21 49:20 χ2 = 2.826 0.419
1) 3.00 (0.95) 2.79 (0.99) χ2 = 10.018 0.349
40) 14.61 (2.51) 13.57 (2.04) F = 26.837 b0.001
43.71) – – t = 2.370 0.019
.54) – – t = 2.110 0.036
.49) – – t = 2.444 0.015
p n = 113, Patients CSRB group n = 36, Controls Paper group n = 63 and Controls CSRB
Paper n = 61, Controls CSRB n = 68; for Antipsychotics total dose: Patient Paper group
SRB group n = 91;and for SANS total: Patients Paper group n = 170, Patients CSRB group
Table 2
Batteries and tests descriptions.
Pen & Paper Battery CogState Research Battery
Cognitive domain Test Outcome
measure
Test Test description Outcome
measure
Processing speed Digit symbola Number of
correct symbols
in 120 s
Groton Maze
Chase Test
Click the tiles of a grid
to trace the path of a target
which moves when it is reached.
Average
number
of correct
moves
per second
Trail Making
Test Ab
Completion
time
Detection task Click as soon as a playing card turns over. Average
reaction
time for
correct
responses
Stroop Test:
Wordc
Number of
correct words
read in 1 min
Stroop Test:
Colorc
Number of
correct colors
named in
1 min
Attention D2 testd Concentration
performance
Identiﬁcation
task
Determine whether a playing card is red
or black as fast as possible after it has ﬂipped
over by clicking the left or right mouse button.
Response
accuracy
Stroop Test:
Inhibitionc
Number of
correct colors
named in
1 min
Working memory Digit Spana Raw score One-back task Determine whether the current playing
card shown is the same or different from
the previous one or the second-previous one.
Response
accuracyCorsi Spatial
Spane
Raw score Two-back task
Visual memory Visual
Reproduction:
Immediate
Recalle
Raw score One-Card
Learning task
Click the left mouse button if he or she had
seen the playing card shown
previously during the task.
Response
accuracy
Visual
Reproduction:
Delayed
Recalle
Raw score Continuous
Paired Associate
Learn and remember abstract pictures
hidden beneath different locations on the screen.
Response
accuracy
Groton Maze
Learning task:
Delayed Recall
Find the hidden pathway by clicking tiles while
avoiding to click tiles located diagonally to
the last correct tile, click the same tile twice or
move backwards on the previously
discovered pathway. This is done over 5 trials.
At the end of the test battery the participant is
asked to remember the hidden
pathway previously learned.
Total number
of errors
Verbal Memory Logical
Memory:
Immediate
Recalle
Raw score International
Shopping List:
Immediate Recall
A list of 16 words is read to the participant
for 3 consecutive trials; after each trial the
participant is asked to recall as many of the
words as possible. Participants are also asked
to recall as many words as possible at the
end of the test battery.
Total number
of words
recalled
over 3 trials
Logical
Memory:
Delayed
Recalle
Raw score International
Shopping List:
Delayed Recall
Total number
of words
recalled
Logical
Memory:
Recognitione
Raw score
Executive functions Block designa Raw score Groton Maze
Learning task
As described above Total number
of errors
after 5 trials
Trail Making
Test Bb
Completion
time
Set-Shifting Task A playing card appears on the screen; if the word “color” appears
above the card, the participant has to guess whether red or black is
correct; if the word is “number” they have to guess whether the
number on the card is correct. Feedback is provided with each
response to teach the participant the underlying rule of each trial
which changes without warning; participants are told at the
beginning of the task that the correct card will change throughout.
Response
accuracy
Social Cognition Missing
Cartoonsf
Number of
correct
responses
Social–Emotional
Cognition task
The participant is shown 4 pictures at a time and must decide
which one is different from the others as quickly
as possible. Stimuli include emotional faces or eyes.
Response
accuracy
a (Wechsler, 1997a).
b (Reitan, 1992).
c (Stroop, 1935).
d (Brikenkamp and Zillmer, 1998).
e (Wechsler, 1997b).
f (O'Sullivan and Guilford, 1976).
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month of cognitive testing were used if available. The SANS total scorewas calculated without the attention items because of their overlap
with the cognitive variables. We also removed the items of poverty of
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tening scale) since factor analytic studies have shown them to belong to
the disorganized symptom cluster (Liddle, 1987; Malla et al., 1993). All
other items of the affective ﬂattening and alogia scale were used as well
as all items of the avolition–apathy and anhedonia–asociality scales. Anti-
psychotic doseswere converted to chlorpromazine equivalents according
to the literature (Jensen and Regier, 2010; Leucht et al., 2014; Woods,
2003) to allow comparison between patient groups.
2.4. Neurocognitive batteries
The tests composing each battery and their outcome measures are
described in Table 2. The pen and paper battery took approximately
2 h to administer, while the CSRB took 1 h.
2.5. Statistical analyses
A composite score was calculated for each cognitive domain in both
neurocognitive batteries by averaging the z-scores for all tests within each
domain and an overall composite score was calculated for each battery by
averaging z-scores of all individual tests. The performance of the matched
control groupswas used as normative data to derive these z-scores. To ver-
ifymatching, the twopatient groups and the two control groupswere com-
pared on age and number of years of education using one-way ANOVAs,
and on sex and parental SES with Chi-square tests. Cognitive performance
between the two patient groups was compared using a mixed-design
ANOVA with cognitive domain as the within group factor and type of
neurocognitive battery as the between group factor. Independent t-tests
were used to compare antipsychotic dosage and symptom totals.
All analyseswere conductedusing SPSS version 20 (SPSS, Chicago, IL,
USA) and were two-tailed with a critical p-value of 0.05, except where
noted. The Visual Reproduction immediate and delayed recalls had to
be log transformed and the Logical Memory: Recognition subtest had
to be square root transformed due to signiﬁcant negative skewness.
All other variables were normally distributed.
3. Results
3.1. Demographic variables
The 4 participant groups did not differ on age, gender or parental SES
but patients had fewer years of education than controls (see Table 1).
The two patient groups differed signiﬁcantly on their average total
dose of antipsychotics taken daily (p = 0.019) and symptom levels
(p=0.036 for SAPS and p=0.015 for SANS) at time of testing. Correla-
tionswere explored between these variables and cognitive performance
yielding onlyweak coefﬁcients and thereforewere not used as covariates
in the main analysis. At the time of cognitive testing, total dose of anti-
psychotics taken daily showed its strongest correlation with processing
speed (r = −0.232), SANS total score correlated most with verbal
memory (r = −0.241) and SAPS total score showed no correlation
with most of the cognitive domains.
3.2. Cognitive performance
The interaction between cognitive domains and type of cognitive
battery used was statistically signiﬁcant (F(6,1662) = 18.63, p b 0.001)
and therefore post-hoc comparisons were performed on each domain
corrected for multiple comparisons (p = 0.05/7). The cohort tested
using the CSRB performed better on the domains of processing
speed, attention, visual memory, and verbal memory than the cohort
tested using the pen and paper battery (all p b 0.001). Performance
did not differ between the cohorts tested using the two types of
batteries in the working memory (p= 0.16), executive functions (p=0.26), and social cognition domains (p=0.14). Fig. 1 shows the cognitive
proﬁles obtained. Table 3 reports patients’ z-scores for individual tests.
A signiﬁcant main effect of type of neurocognitive battery used was
found (F(1,277)=36.88, p b 0.001, partialη2=0.12)where patientswho
did the CSRB performed better overall than those who did the pen and
paper battery. There was also a main effect of cognitive domain
(F(6,1662) = 24.84, p b 0.001, partial η2 = 0.08) indicating that level of
impairment was not similar on all cognitive domains when results on
both batteries were combined. Performance on processing speed was
signiﬁcantly better than that of all other domains (all p b 0.01). Verbal
memory was signiﬁcantly more impaired than all other domains (all
p ≤ 0.001) whereas performance on attention, working memory, visual
memory, and executive functions did not signiﬁcantly differ (all p N 0.1).
Social cognition performance was not different from attention and work-
ing memory but patients had a signiﬁcantly better performance on the
social cognition domain compared to executive functions (p= 0.03).
4. Discussion
The goal of this study was to compare impairment levels of FEP pa-
tients on a traditional pen and paper cognitive battery and the compute-
rized CSRB. Performance on working memory, executive functions and
social cognition did not signiﬁcantly differ but processing speed, atten-
tion, visual and verbal memory performance of patients was better
when assessed with the CSRB (see Fig. 1). We also observed that verbal
memory was the most impaired domain regardless of type of battery
used. Keeping in mind the limitations of our research design, we have
gained a better understanding of the advantages that each battery has
to offer. Overall, the pen and paper battery is more sensitive to deﬁcits
in some domains, while sensitivity is similar to that of the CSRB in
others. Other than the considerably reduced administration and scoring
time required by the CSRB, it should be noted that fewer patients were
excluded from analyses due to incomplete data using the CSRB com-
pared to the pen and paper battery. It is fundamental to keep these dif-
ferences inmindwhen decidingwhich testingmodality is best suited to
a particular research question. We believe the possible explanations for
the differences in processing speed, attention and memory pertain
mostly to the nature of the tasks used, and therefore how cognitive
domains are operationalized in each battery.
The most striking difference between batteries is in the processing
speed and attention. An important factorwhich could explain this variation
is the difference in graphomotor ability demands. The pen and paper bat-
tery uses a variety of tasks in the processing speed and attention domains
which require writing or tracing (Digit Symbol Coding, Trail A, D2) while
this process is completely eliminated in the computerized tasks. This
could mean that even in the very early stages of treatment, patients may
showsomeﬁnemotor skills difﬁculties, however this remains tobedirectly
studied. Some reports suggest that even short neuroleptic exposure can
have an impact onﬁnemotor speed inpatientswhen compared to controls
(Grootens et al., 2009; Krieger et al., 2001). Interestingly, we found that pa-
tients tested with the pen and paper battery were on average more medi-
cated than those who did the CSRB based on chlorpromazine equivalents.
However, this may be an artifact of the conversion formulas: the prescrip-
tion proﬁle across the 11-year span of our data collection shows a sig-
niﬁcant difference in the proportion of patients taking oral versus
injectable antipsychotics (pen and paper: 7% injectable, CSRB: 22%
injectable; χ2 = 10.48, p=0.001). When converting injectable med-
ication to chlorpromazine equivalents the only available formula is
for the oral form of the same molecule but the minimum efﬁcient
dose may not be the same. Further investigations are needed to eval-
uate the best conversion factor for commonly prescribed injectable
antipsychotics to chlorpromazine equivalents.
The Stroop test was used in the processing speed and attention
domains for the pen and paper battery. In addition to the increased
Note: Shown on the y-axis are the average z-scores for each cognitive domain and the overall average z-score for
each battery which can be interpreted as a Cohen’s d since controls performance was used to derive the patients’ z-
scores and therefore the control groups have a mean of 0 and a standard deviation of 1 (Wolf, 1986).
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-1.00
.00
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Attention Working
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memory
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Social
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Composite
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Paper (n=182) CogState (n=97)
Fig. 1. Cognitive performance of patients on the pen and paper battery and the CSRB (Wolf, 1986).
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CSRB tasks, Stroop performance has been shown to correlate with level of
education (Van der Elst et al., 2006), which could have further disadvan-
taged the patients on the pen and paper protocol. Furthermore, the tasks
comprising the processing speed and attention domains of the pen and
paper battery require more complex processing than those used to com-
pose the same domains in the CSRB. Speciﬁcally, the Digit Symbol Coding
task relies on many other cognitive skills over and beyond processing
speed, namely visual scanning, attention, working memory, and mental
ﬂexibility among others. Performance on this task is one of the most im-
paired in schizophrenia among traditional neuropsychological tests
(Dickinson et al., 2007); however, in the CSRB, processing speed is
operationalized differently and this leads to discrepant results. Sim-
ilarly, the Stroop word-reading task is known to activate the lexical
pathway while the CSRB avoids demands on language in most tasks
by using playing cards as stimuli, which reduces cultural confounds.
Visual memory and verbal memory performances were also signiﬁ-
cantly different between batteries. Graphomotor ability could have been
a factor in these domains as well, since the WMS-III Visual ReproductionTable 3
Z-scores for individual neurocognitive tests.
Pen & Paper (n = 182)
Cognitive domain Test z-score M (
Processing speed Digit symbol −1.35 (1.0
Trail Making Test A −0.39 (1.2
Stroop Test: Word −0.96 (1.1
Stroop Test: Color −1.22 (1.2
Attention D2 test −1.38 (1.2
Stroop Test: Inhibition −0.84 (1.0
Working memory Digit Span −0.76 (0.9
Corsi Spatial Span −0.77 (0.9
Visual memory Visual Reproduction: Immediate Recall −1.06 (1.3
Visual Reproduction: Delayed Recall −1.09 (1.0
Verbal Memory Logical Memory: Immediate Recall −1.66 (1.1
Logical Memory: Delayed Recall −1.30 (1.0
Logical Memory: Recognition −1.27 (1.3
Executive functions Block design −0.67 (1.2
Trail Making Test B −1.14 (1.3
Social Cognition Missing Cartoons −0.69 (1.0requires drawing whereas the CSRB visual memory tasks do not. Further-
more, the CSRB tasks rely less on recall than recognition, unlike the pen
and paper tasks, and although still impaired, deﬁcits in recognition are
not as prominent as those of recall (Pelletier et al., 2005) and this may
have inﬂuenced the results. As for the verbal memory, it remains the
most impaired cognitive domain regardless of battery used. Compared to
the performance of healthy controls, FEP patients did better when asked
to recall a list of words which can be grouped in 3 semantic categories
thanwhen asked to recall short stories. Both these tasks offer the possibil-
ity of using semantic information to improve performance but the list pre-
sentation provides increased structure and therefore supports better
encoding. However a ﬁner analysis of the encoding and recall strategies
would be needed to better explain this difference.
We have obtained different results than the previous validation study
of CSRB in chronic schizophrenia. Pietrzak et al. (2009a)which concluded
that both batterieswere equally sensitive to detect cognitive deﬁcits since
the effect sizes for the composite scores were of−1.50 for both the CSRB
andMATRICS battery (Pietrzak et al., 2009a). The effect sizes in our inves-
tigationwere smaller in our pen andpaper battery (d=−1.03) andCSRBCSRB (n = 97)
SD) Test z-score M (SD)
5) Groton Maze Chase Test 0.15 (1.00)
6) Detection task 0.57 (1.58)
1)
2)
3) Identiﬁcation task −0.19 (1.14)
5)
7) One-back task −0.54 (1.23)
8) Two-back task −0.66 (1.27)
6) One-Card Learning task −0.52 (1.24)
7) Continuous Paired Associate −0.33 (0.80)
Groton Maze Learning task: Delayed Recall −0.76 (1.40)
9) International Shopping List: Immediate Recall −1.00 (1.34)
8) International Shopping List: Delayed Recall −0.77 (1.25)
2)
1) Groton Maze Learning task −0.55 (1.31)
8) Set-Shifting Task −0.94 (1.39)
9) Social- Emotional Cognition task −0.48 (1.22)
145A. Benoit et al. / Schizophrenia Research: Cognition 2 (2015) 140–145(d=−0.48). This is most likely due to the differences in clinical charac-
teristics of patients between the two studies.While Pietrzak et al. (2009a)
have limited their investigation to schizophrenia, our cohort includes
other types of FEP such as patients with bipolar disorder and major de-
pression disorder which are known to be less cognitively impaired than
ﬁrst-episode schizophrenia patients (Barch, 2009; Hill et al., 2009). It
should be noted also that Pietrzak et al. (2009a) did not use all the CSRB
tasks available in the software (one task per cognitive domain except
forworkingmemorywas used) and thismayhave inﬂuencedpatient per-
formance differently (Pietrzak et al., 2009a).
4.1. Limitations
This study has some limitations. First, the administration of the two
types of batteries could not be randomized or counter-balanced since
this is a historical cohort study. Second, there were signiﬁcant
differences between the two patient groups in symptoms at the time
of testing. These differences could be partly explained by the 3week dif-
ference in the administration of the battery between the two groups
even though this difference was not signiﬁcant, or, as stated earlier,
an artifact of the available chlorpromazine equivalents conversion
equations. As noted earlier, the symptom severity was not assessed on
the day of cognitive testing but within 1 month of testing, which may
not always reﬂect precisely the symptom severity on the day of testing.
Finally, the number of patients in each group was uneven and this may
have affected the magnitude of statistical effects calculated.
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